Aidoc Secures $150M in Series E to Expand Clinical AI Decision Support Platform

Aidoc just pulled in $150M in Series E funding, and it lands different when the machine reading your scans just got a capital injection from Goldman Sachs Alternatives, with General Catalyst, SoftBank Investment Advisors, and NVentures riding shotgun. That is not just money. That is conviction showing up in a tailored suit, asking healthcare how fast it is willing to evolve.

Respect where it is due. Elad Walach, Co-founder and CEO, and Michael Braginsky, Co-founder and CTO, did not stumble into this lane. They built it, one scan at a time, turning radiology from a constraint into a signal amplifier. Alongside Guy Reiner, Co-founder and Chief Architect, they started with a simple premise back in 2016: if imaging is the heartbeat of modern medicine, why is it still waiting in line? So they taught software to see, to prioritize, to nudge clinicians before seconds turn into consequences. Quiet work. Life loud impact.

Now Aidoc is not just reading images, it is orchestrating decisions. An always on clinical AI layer that does not clock out, does not blink, and does not miss the subtle shadows that matter. Hospitals are not buying tools anymore, they are buying time. And Aidoc sells time back to systems drowning in volume, staffing gaps, and diagnostic drag, with Jesse Ehrenfeld, MD, MPH, Global Chief Medical Officer, and Aswin Chandrakantan, MD, President and Chief Commercial Officer, helping translate product into practice at scale.

Over 1,200 hospitals plugged in globally. More than 400 people behind the curtain making it hum. $500M+ in total funding now in the tank. You do not get there by pitching hype. You get there by embedding deep into workflows, surviving procurement gauntlets, earning trust where mistakes are not tolerated.

The real play here is not another point solution flexing accuracy metrics. It is platform gravity. Aidoc is stacking use cases across radiology, emergency, surgery, and now pushing into oncology and cardiovascular. The more surface area they cover, the harder it becomes to rip them out. That is how you move from vendor to infrastructure.

Goldman Sachs Alternatives leading this round tells you something else. Clinical AI is not a science project anymore. It is an asset class. When capital at that level leans in, it is betting that hospitals will standardize around platforms that think, triage, and coordinate at scale.

Founders chasing this space should pay attention. Aidoc did not try to boil the ocean on day one. They picked a wedge, owned it, proved outcomes, then expanded with precision. No shortcuts, no vanity features, just relentless integration into the messy reality of healthcare.

This is what happens when clinical urgency meets capital efficiency. Aidoc is not just scaling a product, it is scaling a layer inside modern medicine, where every second shaved off a diagnosis compounds across millions of cases. The market is not reacting to potential. It is responding to proof already in motion.